Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.23). Lexicon Pharmaceuticals posted earnings per share of ($0.40) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.5%. The firm is scheduled to report its next earnings results on Thursday, May 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to $0.21. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.85) to $0.19. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 192.53%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. The company’s revenue was down 49.7% compared to the same quarter last year.
Several research firms have recently commented on LXRX. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 25th. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, Gabelli downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average price target of $20.38.
NASDAQ LXRX opened at $7.74 on Thursday. The company has a market cap of $809.79 million, a PE ratio of -6.79 and a beta of 0.70. Lexicon Pharmaceuticals has a 52 week low of $4.26 and a 52 week high of $13.97.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pegasus Asset Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $66,000. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $73,000. CWM Advisors LLC increased its holdings in shares of Lexicon Pharmaceuticals by 30.2% during the fourth quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 3,030 shares in the last quarter. D.A. Davidson & CO. bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $87,000. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Lexicon Pharmaceuticals by 409.3% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 11,862 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: What is the return on assets formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.